178 related articles for article (PubMed ID: 5767441)
1. [Experiences with ornithine-aspartate in liver diseases].
Aschke J
Med Welt; 1969 Mar; 12():657-62. PubMed ID: 5767441
[No Abstract] [Full Text] [Related]
2. [Further clinical experiences with ornithine aspartate in liver diseases].
Wotzka R; Weber D
Ther Ggw; 1972 Mar; 111(3):400-12. PubMed ID: 5024593
[No Abstract] [Full Text] [Related]
3. [On the therapy of liver diseases with ornithine aspartate].
Melzer H; Weber D; Wotzka R
Med Klin; 1969; 64(35):1541-4. PubMed ID: 5354488
[No Abstract] [Full Text] [Related]
4. [Personal experiences in the treatment of internal diseases with ornithine aspartate].
Perinović M; Robović Z; Grujić M; Ljubojević S
Med Arh; 1969; 23(3):29-32. PubMed ID: 5200044
[No Abstract] [Full Text] [Related]
5. [Clinical experiences in liver diseases (specially in patients with fatty liver due to alcoholism and food poisoning) under monotherapy with ornithine aspartate].
Hunold W
Z Allgemeinmed; 1973 Apr; 49(10):469-72. PubMed ID: 4580434
[No Abstract] [Full Text] [Related]
6. [Clinical study on the effects of L-ornithine-L-aspartate on liver dysfunction].
Kosozu K
Iryo; 1966 Apr; 20(4):339-46. PubMed ID: 5974192
[No Abstract] [Full Text] [Related]
7. [Clinical experiences with heparmez].
Baumann M
Z Allgemeinmed; 1970 Jun; 46(17):895-900. PubMed ID: 5509064
[No Abstract] [Full Text] [Related]
8. [Enzymatic therapy in hepatology with ornithine carbamol transferase].
Monges H; Hancy A; Codinach N
Mars Med; 1971; 108(12):881-5. PubMed ID: 5145506
[No Abstract] [Full Text] [Related]
9. [Influence of ornithine aspartate on the experimentally induced hyperammoniemia. Clinico-experimental study].
Henglein-Ottermann D
Ther Ggw; 1976 Sep; 115(9):1504-18. PubMed ID: 968783
[No Abstract] [Full Text] [Related]
10. [Our clinical experience with ornithine aspartate].
Szirmai E
Minerva Med; 1971 Jun; 62(47):2376-82. PubMed ID: 5087700
[No Abstract] [Full Text] [Related]
11. [Protection of the liver and liver therapy with Hepamerz].
Heynen U
Z Allgemeinmed; 1970 Jan; 46(2):87-8. PubMed ID: 5439291
[No Abstract] [Full Text] [Related]
12. [Study of the treatment of liver damage due to several causes in tuberculosis, using ornithine-aspartate].
Seki S
Iryo; 1966 Apr; 20(4):354-63. PubMed ID: 5974194
[No Abstract] [Full Text] [Related]
13. [Effects of treatment with nucleotides and aspartic acid in chronic liver diseases].
Iencica R
Med Interna (Bucur); 1972 Dec; 24(12):1449-53. PubMed ID: 4655566
[No Abstract] [Full Text] [Related]
14. [Clinical trial of alpha ornithine ketoglutarate].
Linquette M; Fossati P; Hubschman B
Lille Med; 1969 Apr; 14():Suppl 3:512-5. PubMed ID: 5376446
[No Abstract] [Full Text] [Related]
15. [Use of ornithine carbamoyltransferase in the treatment of liver diseases].
Caruso N; De Jacobis M; Roccato M; Sequino A; Sgoifo B; Tinello M
Clin Ter; 1984 Jul; 110(1):37-44. PubMed ID: 6237844
[No Abstract] [Full Text] [Related]
16. [Clinico-statistical study of the therapeutic activity of coenzyme A in various hepatopathies].
Ruberti A; Tobaldin G; Montanari MG; Castellani P
Clin Ter; 1971 May; 57(4):309-42. PubMed ID: 5110947
[No Abstract] [Full Text] [Related]
17. [Betaine aspartate in the therapy of liver diseases].
Cairella M; Volpari B
Clin Ter; 1972 Mar; 60(6):513-34. PubMed ID: 5038777
[No Abstract] [Full Text] [Related]
18. [Betaine aspartate in the hepato-digestive domain].
Cachin M; Pergola F
Sem Ther; 1966 Oct; 42(8):423-4. PubMed ID: 5994378
[No Abstract] [Full Text] [Related]
19. [Trial of LL 650 in various hepatic diseases].
Savoye B; Dietsch R; Chapuy M; Girard M
J Med Lyon; 1972 May; 53(228):675-6 passim. PubMed ID: 5084113
[No Abstract] [Full Text] [Related]
20. [Glucocorticotherapy in hepatic diseases].
Boroń P; Borzuchowska A; Modzelewski T
Przegl Lek; 1970; 26(10):753-5. PubMed ID: 5484242
[No Abstract] [Full Text] [Related]
[Next] [New Search]
